[go: up one dir, main page]

DE69127829D1 - Expression von pace in wirtszellen und verfahren zu dessen verwendung - Google Patents

Expression von pace in wirtszellen und verfahren zu dessen verwendung

Info

Publication number
DE69127829D1
DE69127829D1 DE69127829T DE69127829T DE69127829D1 DE 69127829 D1 DE69127829 D1 DE 69127829D1 DE 69127829 T DE69127829 T DE 69127829T DE 69127829 T DE69127829 T DE 69127829T DE 69127829 D1 DE69127829 D1 DE 69127829D1
Authority
DE
Germany
Prior art keywords
pace
expression
host cells
amino acid
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69127829T
Other languages
English (en)
Other versions
DE69127829T2 (de
Inventor
Philip Barr
Anthony Brake
Randal Kaufman
Patricia Tekamp-Olson
Louise Wasley
Polly Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27505162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69127829(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC, Chiron Corp filed Critical Genetics Institute LLC
Application granted granted Critical
Publication of DE69127829D1 publication Critical patent/DE69127829D1/de
Publication of DE69127829T2 publication Critical patent/DE69127829T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69127829T 1990-11-26 1991-11-26 Expression von pace in wirtszellen und verfahren zu dessen verwendung Expired - Lifetime DE69127829T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62109290A 1990-11-26 1990-11-26
US62144390A 1990-11-29 1990-11-29
US62085990A 1990-11-29 1990-11-29
US62145790A 1990-11-30 1990-11-30
PCT/US1991/008725 WO1992009698A1 (en) 1990-11-26 1991-11-26 Expression of pace in host cells and methods of use thereof

Publications (2)

Publication Number Publication Date
DE69127829D1 true DE69127829D1 (de) 1997-11-06
DE69127829T2 DE69127829T2 (de) 1998-03-19

Family

ID=27505162

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69127829T Expired - Lifetime DE69127829T2 (de) 1990-11-26 1991-11-26 Expression von pace in wirtszellen und verfahren zu dessen verwendung

Country Status (10)

Country Link
US (3) US5460950A (de)
EP (2) EP0785273A1 (de)
JP (2) JP4236698B2 (de)
AT (1) ATE158816T1 (de)
CA (1) CA2096418C (de)
DE (1) DE69127829T2 (de)
DK (1) DK0574402T3 (de)
ES (1) ES2109336T3 (de)
IE (1) IE914102A1 (de)
WO (1) WO1992009698A1 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935815A (en) * 1989-10-25 1999-08-10 Katholieke Universiteit Leuven Process for micro biological production of proteins
ES2109336T3 (es) * 1990-11-26 1998-01-16 Genetics Inst Expresion de pace en celulas huesped y metodos de utilizacion de la misma.
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US6348327B1 (en) * 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
CA2131549A1 (en) * 1992-03-09 1993-09-16 Philip J. Barr Compositions and methods for pace 4 and 4.1 gene and polypeptides in cells
US5846802A (en) * 1992-04-15 1998-12-08 Buxton; Frank Fungal Protease
WO1994010309A1 (en) 1992-10-23 1994-05-11 Genetics Institute, Inc. Novel p-selectin ligand protein
US6277975B1 (en) * 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5604201A (en) * 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
WO1996027018A1 (en) * 1995-02-27 1996-09-06 Abbott Laboratories A plasmid for expressing modified recombinant proteins in a bacterial system
US5942254A (en) * 1995-02-27 1999-08-24 Abbott Laboratories Phosphorylated recombinant human β-casein expressed in a bacterial system
US5710044A (en) * 1995-02-27 1998-01-20 Abbott Laboratories Plasmid for expressing phosphorylated recombinant proteins in a bacterial system
WO1996027017A1 (en) * 1995-02-27 1996-09-06 Abbott Laboratories A method for expressing modified recombinant proteins in a bacterial system
US5807702A (en) * 1995-02-27 1998-09-15 Abbott Laboratories Method for expressing phosphorylated recombinant human β-casein in a bacterial system
AT404838B (de) 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
JPH09295945A (ja) * 1996-04-30 1997-11-18 Hoechst Yakuhin Kogyo Kk 成熟型骨誘導因子の製造方法
US6518411B1 (en) * 1996-11-22 2003-02-11 University Of Iowa RGS compositions and therapeutic and diagnostic uses therefor
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
GB9704305D0 (en) * 1997-03-01 1997-04-23 Univ Manchester Procollagen assembly
US6153420A (en) * 1997-04-24 2000-11-28 Zymogenetics, Inc. Serine protease polypeptides and materials and methods for making them
US7081519B1 (en) 1997-04-24 2006-07-25 Zymogenetics, Inc. Antibodies to serine protease polypeptides
BR9808718A (pt) * 1997-05-06 2000-07-11 Zymogenetics Inc Polinucleotìdeo isolado, sequência de polinucleotìdeo isolado, vetor de expressão, célula cultivada, construção de dna, proteìna de fusão, polipeptìdeo isolado, processos para produzir um polipeptìdeo de convertase pró-hormÈnio humano 4, para determinar substratos de pró-hormÈnio de polipeptìdeo, para detectar, em uma amostra de teste, a presença de um modulador de atividade de polipeptìdeo de convertase pró-hormÈnio humano, e, para produzir um anticorpo para polipeptìdeo de convertase pró-hormÈnio humano 4
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
CA2249648A1 (en) * 1998-11-04 2000-05-04 Nabil G. Seidah Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
EP1127154B1 (de) * 1998-11-06 2008-09-10 Novo Nordisk Health Care AG Verfahren zur herstellung von faktor vii
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
US6511832B1 (en) * 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
IL149416A0 (en) * 1999-11-19 2002-11-10 Solvay Pharm Bv Human enzymes of the metalloprotease family
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6596526B1 (en) * 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
JP4361730B2 (ja) * 2000-10-02 2009-11-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ビタミンｋ−依存性タンパク質の生成方法
WO2002039951A2 (en) * 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
WO2002094176A2 (en) * 2001-05-18 2002-11-28 Solvay Pharmaceuticals Gmbh Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments
US20040002468A1 (en) * 2001-08-08 2004-01-01 Genzyme Corporation Methods of treating diabetes and other blood sugar disorders
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
BR0309576A (pt) * 2002-04-30 2005-02-09 Maxygen Holdings Ltd Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
AU2003241599A1 (en) * 2002-05-22 2003-12-12 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia a
WO2004083361A2 (en) * 2003-03-20 2004-09-30 Maxygen Holdings Ltd. FVII OR FVIIa VARIANTS
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
NZ544728A (en) * 2003-06-19 2009-04-30 Bayer Healthcare Llc Factor VII or VIIa Gla domain variants
ES2339710T5 (es) 2003-09-23 2017-10-05 University Of North Carolina At Chapel Hill Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K
US20050107318A1 (en) * 2003-11-17 2005-05-19 Samuel Wadsworth Methods of treating diabetes and other blood sugar disorders
US20050196864A1 (en) * 2004-02-10 2005-09-08 Goldman Steven A. Induction and high-yield preparative purification of mesencephalic dopaminergic neuronal progenitor cells and dopaminergic neurons from human embryonic stem cells
AU2005243187A1 (en) * 2004-05-11 2005-11-24 Wyeth Oligonucleotide arrays to monitor gene expression and methods for making and using same
ES2390082T5 (es) * 2004-06-30 2018-01-19 Nektar Therapeutics Conjugados de resto de Factor IX y polímeros
AU2005282380A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
JP2008512098A (ja) * 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
JP2009502140A (ja) 2005-07-22 2009-01-29 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 光活性化陽イオンチャネルおよびその使用
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
EP1969127B8 (de) * 2005-12-21 2017-12-13 Aptevo BioTherapeutics LLC Verfahren zur herstellung biologisch wirksamer vitamin-k-abhängiger proteine mit rekombinanten verfahren
US7566565B2 (en) * 2006-03-24 2009-07-28 Syntonix Pharmaceuticals, Inc. PC5 as a factor IX propeptide processing enzyme
EP1854455B1 (de) 2006-05-10 2009-10-07 Biocompatibles UK Limited GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
WO2008086470A1 (en) 2007-01-10 2008-07-17 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8401609B2 (en) 2007-02-14 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
EP2517714A1 (de) 2007-04-26 2012-10-31 Inspiration Biopharmaceuticals, Inc. Rekombinante Vitamin-K-abhängige Proteine mit hohem Sialsäuregehalt und Verfahren zu ihrer Herstellung
WO2008141824A2 (en) 2007-05-22 2008-11-27 Baxter International Inc. Preparative purification process for human furin
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
SI2574677T1 (sl) 2007-12-27 2017-11-30 Baxalta GmbH Procesi celične kulture
JP5806465B2 (ja) * 2007-12-31 2015-11-10 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 実質的に動物性タンパク質を含まない組換えフリンおよび実質的に動物性タンパク質を含まない組換えフリンを作製するための方法
US8603790B2 (en) 2008-04-23 2013-12-10 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
MX2010012986A (es) 2008-05-29 2011-05-25 Univ Leland Stanford Junior Linea de celulas, sistema y metodo para control optico de mensajeros secundarios.
AU2009260027B2 (en) 2008-06-17 2015-12-03 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for controlling cellular development
EP2303406B1 (de) 2008-06-17 2016-11-09 The Board of Trustees of the Leland Stanford Junior University Vorrichtungen zur optischen stimulierung von zielzellen mit einem optischen transmissionselement
WO2010006049A1 (en) 2008-07-08 2010-01-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
EP2163243A1 (de) 2008-09-12 2010-03-17 Biocompatibles UK Limited Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
EP2251028A1 (de) 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Behandlung von Augenerkrankungen unter Verwendung eingekapselter Zellen, die einen antiangiogenetischen Faktor und/oder einen neuroprotektiven Faktor codieren und sekretieren
EP3399024A1 (de) 2010-03-17 2018-11-07 The Board of Trustees of The Leland Stanford Junior University Lichtempfindliche ionendurchgangsmoleküle
WO2012006623A1 (en) * 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
SG186875A1 (en) 2010-07-09 2013-02-28 Biogen Idec Hemophilia Inc Chimeric clotting factors
WO2012034704A1 (en) 2010-09-15 2012-03-22 Biocompatibles Uk Ltd. Treatment of vascular diseases using encapsulated cells encoding and secreting glp-1, or a fragment or variant thereof
US9522288B2 (en) 2010-11-05 2016-12-20 The Board Of Trustees Of The Leland Stanford Junior University Upconversion of light for use in optogenetic methods
WO2012061744A2 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Stabilized step function opsin proteins and methods of using the same
AU2011323226B2 (en) 2010-11-05 2015-03-12 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
JP6328424B6 (ja) 2010-11-05 2018-07-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 記憶機能の制御および特性化
CA2816976C (en) 2010-11-05 2019-12-03 The Board Of Trustees Of The Leland Standford Junior University Optogenetic control of reward-related behaviors
AU2011323237B2 (en) 2010-11-05 2015-11-12 The Board Of Trustees Of The Leland Stanford Junior University Optically-controlled CNS dysfunction
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
WO2012088222A2 (en) 2010-12-21 2012-06-28 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
US20140051832A1 (en) * 2011-03-11 2014-02-20 Universidade De São Paulo - Usp Method for the production of recombinant human factor viii
JP5797837B2 (ja) 2011-06-02 2015-10-21 バクスター、インターナショナル、インコーポレイテッド 組換えフューリン製剤
AU2012352429B2 (en) 2011-12-16 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
EP2814955A1 (de) * 2012-02-14 2014-12-24 Portola Pharmaceuticals, Inc. Verfahren zur herstellung eines rekombinanten gegenmittels gegen faktor-xa-inhibitor
ES2728077T3 (es) 2012-02-21 2019-10-22 Univ Leland Stanford Junior Composiciones para el tratamiento de trastornos neurogénicos del suelo pélvico
EP2863940A4 (de) 2012-06-08 2016-08-10 Biogen Ma Inc Chimäre gerinnungsfaktoren
CN104519897A (zh) 2012-06-08 2015-04-15 比奥根艾迪克Ma公司 促凝血化合物
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
CN105246550A (zh) 2013-03-15 2016-01-13 小利兰·斯坦福大学托管委员会 行为状态的光遗传学控制
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
EP2991491B1 (de) 2013-04-29 2019-12-25 The Board of Trustees of the Leland Stanford Junior University Vorrichtungen, systeme und verfahren zur optogenetischen modulation von wirkungspotentialen in zielzellen
WO2015023782A1 (en) 2013-08-14 2015-02-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for controlling pain
PT3149163T (pt) 2014-05-26 2020-09-03 Academisch Ziekenhuis Leiden Proteínas proemostáticas para o tratamento de hemorragia
AR102048A1 (es) 2014-08-12 2017-02-01 Baxalta Inc Producción del factor x completamente procesado y funcional en un sistema de expresión de mamífero de secreción de furina
JP7095990B2 (ja) 2014-09-18 2022-07-05 シーダーズ－サイナイ メディカル センター 線維症を治療するための組成物及び方法
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
US20180110823A1 (en) 2015-04-22 2018-04-26 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
WO2016209654A1 (en) 2015-06-22 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2855719A1 (de) 1978-12-22 1980-07-10 Siemens Ag Zahnaerztliche handstueckanordnung
US4336336A (en) 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
ES8306797A1 (es) 1981-04-29 1983-06-01 Biogen Nv Un metodo para producir un polipeptido.
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4546083A (en) 1983-04-22 1985-10-08 Stolle Research & Development Corporation Method and device for cell culture growth
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
EP0136907A3 (de) 1983-10-03 1986-12-30 Genentech, Inc. Xenogeneisches Expressionskontrollsystem, Verfahren zu dessen Verwendung, dieses enthaltende Expressionsvektoren, mit denselben transformierte Zellen und daraus hergestellte heterolose Proteine
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
DE3587759T2 (de) 1984-05-11 1994-07-07 Chiron Corp., Emeryville, Calif. Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.
US5077204A (en) * 1984-06-21 1991-12-31 Chiron Corporation Yeast endopeptidase for basic amino-acid site cleavage, preparation and use
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
ATE63757T1 (de) 1985-03-28 1991-06-15 Chiron Corp Expression durch verwendung von fusionsgenen fuer proteinproduktion.
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4770999A (en) * 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
ES2061482T3 (es) 1986-05-02 1994-12-16 Gist Brocades Nv Metodo para la identificacion de secuencias de señal secretora para sintesis de proteina extracelular en bacillus.
EP0246709A1 (de) * 1986-05-20 1987-11-25 Stichting Katholieke Universiteit Rekombinantes DNS, komplementäre DNS, Protein, Antikörper und Verfahren zum Nachweis von Tumorzellen
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
WO1988002406A2 (en) 1986-10-02 1988-04-07 Massachusetts Institute Of Technology Methods of regulating metabolic stability of proteins
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US4870023A (en) * 1987-03-16 1989-09-26 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
DK175243B1 (da) 1987-03-23 2004-07-19 Zymogenetics Inc Ekspressionsvektor, der er i stand til at styre ekspression af heterologe gener eller cDNA i gær, gærværtscelle samt fremgangsmåde til öget produktion af proteiner i gærværtsceller
GB8712540D0 (en) * 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US4929553A (en) * 1987-05-29 1990-05-29 Canadian Patents & Development Ltd. Protease for specific processing of secreted proteins
US5041378A (en) * 1987-08-11 1991-08-20 Cetus Corporation Procaryotic xylose isomerase muteins
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4973551A (en) 1988-01-15 1990-11-27 Merck & Co., Inc. Vector for the expression of fusion proteins and protein immunogens
JP2643968B2 (ja) * 1988-02-03 1997-08-25 サントリー株式会社 Ｋｅｘ２エンドプロテアーゼ及びその製造方法
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
JP2693800B2 (ja) 1988-12-28 1997-12-24 甲府日本電気株式会社 浮動小数点データ総和演算回路
NL9000917A (nl) * 1989-10-25 1991-05-16 Holland Biotechnology Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van (precursor) eiwitten en voor de (micro) biologische bereiding van eiwitten.
CN1024746C (zh) * 1989-12-20 1994-06-01 李清祈 具热能调节作用构件的煮器
ES2109336T3 (es) * 1990-11-26 1998-01-16 Genetics Inst Expresion de pace en celulas huesped y metodos de utilizacion de la misma.
US5780285A (en) * 1995-03-03 1998-07-14 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing dibasic residues
CA2438874A1 (en) 2001-03-14 2002-09-19 Eli Lilly And Company Fluorinated trienes and their use as rxr modulators

Also Published As

Publication number Publication date
CA2096418A1 (en) 1992-05-27
ATE158816T1 (de) 1997-10-15
DE69127829T2 (de) 1998-03-19
WO1992009698A1 (en) 1992-06-11
EP0785273A1 (de) 1997-07-23
JP2008194050A (ja) 2008-08-28
DK0574402T3 (da) 1998-05-18
EP0574402B1 (de) 1997-10-01
CA2096418C (en) 2001-11-20
US5965425A (en) 1999-10-12
JP4236698B2 (ja) 2009-03-11
EP0574402B2 (de) 2012-08-01
ES2109336T3 (es) 1998-01-16
IE914102A1 (en) 1992-06-03
EP0574402A4 (en) 1994-08-24
US5460950A (en) 1995-10-24
JPH06504435A (ja) 1994-05-26
US5986079A (en) 1999-11-16
EP0574402A1 (de) 1993-12-22

Similar Documents

Publication Publication Date Title
DE69127829D1 (de) Expression von pace in wirtszellen und verfahren zu dessen verwendung
ATE91714T1 (de) Transformation von trichoderma.
ES2142363T3 (es) Materiales y metodos para la hipersecrecion de aminoacidos.
DE68929115D1 (de) Verfahren zur Herstellung von menschlichem Serumalbumin in Hefe
ATE79403T1 (de) Herstellung von thrombin-inhibitoren.
IL68366A (en) Process for expressing a gene encoding a protein comprising the enzymatic portion of human urokinase in a microorganism or cell culture
ATE140962T1 (de) Dns-klone von menschlichem thrombomodulin
NZ239357A (en) Human mk gene and protein sequence
NO177794C (no) Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten
NO177793C (no) Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten
DE3683512D1 (de) Verfahren zur optischen isomerisierung von optisch aktiver aminosaeure und verfahren zur herstellung von optisch aktiver aminosaeure.
FR2607517B2 (fr) Vecteurs d'expression de variants de l'hirudine dans les levures, procede et produit obtenu
ATE26986T1 (de) Verfahren zur loesung von peptiden und proteinen, hierdurch erhaltene loesungen und deren verwendung.
WO1994025590A3 (en) Trichohyalin and transglutaminase-3 and methods of using same
DE69430975D1 (de) Verfahren zur Herstellung von Proteinen
ATE102994T1 (de) Verfahren zur herstellung von proteinen.
FI873168A0 (fi) Foerfarande foer kontinuerlig separering genom elektrofores och elektro-osmos av elektriskt laddade pulverartade fasta aemnen.
EP0271964A3 (en) Method for preparing protein hydrolysates soluble in an acid environment, and the hydrolysates obtained
DK408488A (da) Fremgangsmaade til bestemmelse af tilstedevaerelse af et gen derkoder for syntese af beta-lactamase i en mikroorganisme, og dna-prober til brug ved fremgangsmaaden
DE3667802D1 (de) Verfahren zur elektrochemischen oxydation von alkylpyridinen.
DE3670308D1 (de) Enzym, verfahren zu dessen gewinnung und verwendung zur herstellung von n-(l-aspartyl-1)l-phenylalaninmethylester.
DE3677851D1 (de) Verfahren zur steigerung der produktion von rekombinantem protein in hefearten der gattung saccharomyces.
ATE84314T1 (de) Mikroorganismen, die fremdproteinenthaltende pili tragen, isolierte pili, verfahren zur ausscheidung von proteinen in verwendung dieser pili und deren nutzen.
AT385517B (de) Verfahren zur gewinnung von proteinhaeltigen mikroorganismenzellen
DE3784891D1 (de) Verfahren zur isolierung von saeurestabilen, biologisch aktiven proteinen.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: GENETICS INSTITUTE,LLC(N.D.GES.D.STAATES DELAWARE)

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV

8327 Change in the person/name/address of the patent owner

Owner name: GENETICS INSTITUTE,LLC (N.D.GES.D.STAATES DELA, US

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

8328 Change in the person/name/address of the agent

Representative=s name: DF-MP, 80333 MUENCHEN

R102 Epo decision maintaining patent in amended form now final

Ref document number: 574402

Country of ref document: EP

R102 Epo decision maintaining patent in amended form now final

Ref document number: 574402

Country of ref document: EP

Effective date: 20120801